<DOC>
	<DOCNO>NCT02384330</DOCNO>
	<brief_summary>This study aim estimate cost botulinum toxin A utilization standard practice treatment upper limb spasticity post-stroke Portugal . It consider three use locally available brand botulinum toxin A show similar efficacy safety profile thus make relevant understand choose one another brand depend directly economic factor . The study estimate direct indirect drug-associated cost determinant variable price drug standard drug dose use clinical practice .</brief_summary>
	<brief_title>Botulinum Toxin A Associated Costs Treatment Upper Limb Spasticity Post Stroke</brief_title>
	<detailed_description>A comparison perform direct cost associate therapeutic strategy cost analysis assume quality life value may different patient treat treatment .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Patients diagnose poststroke upper limb spasticity Patients currently treat Dysport® , Botox® Xeomin® Patients stabilize therapeutic point view switch treatment least 2 last administration Patients give write informed consent participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>